• Boceprevir is looking more and more like a commercial dud with each passing day (#msg-54317080, #msg-56152791).
• Gardasil has turned out to be a tough sell (#msg-54120045).
• The Zetia/Vytorin franchise probably can’t be rejuvenated (#msg-26000935).
• The NDA for a Lipitor+Zetia combo pill got a Refusal-to-File Letter (#msg-43169725).
• Cordaptive is delayed until 2013—or later (#msg-30170058).
• GILD and GSK have Isentress in their crosshairs and could supplant it with qD integrase inhibitors (#msg-30900183, #msg-55878096).
• MRK has been oddly quiet lately about TRA, the purported antiplatelet blockbuster-in-waiting that MRK acquired from SGP.
• Singulair, MRK’s largest drug, goes off-patent in less than two years.
• I expect MRK to lose the Remicade/Simponi arbitration and thereby forfeit the ex-US rights to these drugs or have to pay JNJ a hefty concession (#msg-55521924).
Did I miss anything?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.